Travere Therapeutics (NASDAQ:TVTX) is in focus after a fresh update tied to rare disease therapies, with market attention on ...

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced it will report second quarter 2026 financial results on Tuesday, August 4, 2026, after the close of the U.S. financial markets. The Company ...

Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.

Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Travere Therapeutics, Inc. (NASDAQ: TVTX) breached their fiduciary duties to shareholders ...

Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on July 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 41,600 ...

SAN DIEGO, July 10, 2026--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on July 10, 2026, the Compensation Committee of its Board of Directors granted inducement ...

Travere Therapeutics spent the first half of 2026 converting a single approved medicine into a broader commercial and pipeline story. A rare-disease drugmaker built around FILSPARI, its treatment for ...

Everest Medicines (HKEX 1952.HK, 'Everest', or the 'Company'), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative ...